Investment Rating - The report maintains a "Buy" rating for the company [5][11]. Core Insights - The company has demonstrated significant growth in IP revenue, with a more than doubling of income from IP-related businesses, particularly in ToB licensing and a rapidly developing ToC segment [11]. - The company's total revenue for FY26H1 reached 4.05 billion RMB, representing a year-on-year increase of 33%, while net profit attributable to shareholders was 520 million RMB, up 54% [8][11]. - The report highlights a strategic shift in the film investment approach, focusing on lower-risk, high-quality content, while the live performance segment is expanding both domestically and internationally [11]. Financial Data and Profit Forecast - The company’s revenue projections for FY2024 to FY2028 are as follows: - FY2024: 5.036 billion RMB (YoY +43%) - FY2025: 6.702 billion RMB (YoY +33%) - FY2026E: 8.510 billion RMB (YoY +27%) - FY2027E: 9.982 billion RMB (YoY +17%) - FY2028E: 11.336 billion RMB (YoY +14%) [10][12]. - Net profit attributable to ordinary shareholders is forecasted to grow significantly, with estimates of 1.043 billion RMB for FY2026E, reflecting a 187% increase from FY2025 [10][12]. - The report anticipates a steady increase in earnings per share, projected to reach 3.52 RMB in FY2026E [10][12]. Business Segment Performance - The IP derivative business saw a revenue increase of 105% in FY26H1, with a focus on high-quality IPs and expanding retail brand operations [11]. - The live performance segment generated 1.34 billion RMB in revenue for FY26H1, marking a 14.5% increase, despite some pressure on profit margins due to international expansion efforts [11]. - The film segment reported a revenue decline of 15% in FY26H1, prompting a strategic pivot towards lower-budget, high-quality films [11].

Investment Rating - The investment rating for the company is positioned in the mid-to-lower range, with an AHP score of 2.38, placing it in the 38.9% percentile of the overall score [2][5]. Core Insights - The company, Baiaosaitu, is a leading preclinical CRO and biotechnology firm, focusing on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development. The gene editing technology is a significant foundation for its business, having developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [2][12]. - The company has expanded its business into innovative model animal sales, having developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice. The establishment of a production center compliant with AAALAC international standards supports large-scale breeding and supply of model animals [12][30]. - The company has established a comprehensive pharmacology and efficacy evaluation system, serving approximately 950 partners globally and completing over 6,350 drug evaluation projects. It has collaborations with 9 of the top 10 global pharmaceutical companies in the pharmacology and efficacy sector [2][18]. Summary by Sections AHP Score and Expected Allocation Ratio - The AHP score for Baiaosaitu is 2.38, indicating a mid-to-lower performance level in the AHP model [5][6]. Company Fundamentals and Highlights - Baiaosaitu has built platforms for gene editing, model animal breeding, preclinical pharmacology evaluation, and antibody drug development, evolving from a single-service biotechnology company to a leading biopharmaceutical enterprise [6][12]. - The company’s revenue composition shows that model animal sales accounted for approximately 44% of total revenue in the first half of 2025, followed by antibody development and preclinical pharmacology services [7][8]. Financial Comparison with Peers - From 2022 to the first half of 2025, Baiaosaitu's revenue was lower than that of comparable companies, with revenues of 5.34, 7.17, 9.80, and 6.21 billion yuan respectively. However, the net profit turned positive in 2024, with a net profit margin that improved over time [22][24]. - The company’s gross margin was relatively high, with figures of 73.38%, 70.59%, 77.67%, and 74.39% from 2022 to the first half of 2025, outperforming the average of comparable companies [24][25]. Fundraising Projects and Development Vision - The company plans to raise funds for projects including the construction of a drug early research service platform, antibody drug research and evaluation projects, and preclinical research projects, which are expected to enhance its core competitiveness and solidify its industry position [30][31].

Investment Rating - The report assigns a rating of "Subscribe" for the company, with an AHP score of 2.38, placing it in the 38.9% percentile of the AHP model [7][8]. Core Insights - The company, BaiAoSaiTu, is positioned as a leading preclinical CRO and biotechnology firm, with a focus on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development [8][9]. - The company has developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [13][14]. - BaiAoSaiTu has established a comprehensive preclinical pharmacology and efficacy evaluation system, collaborating with nine of the top ten global pharmaceutical companies [18][20]. - The company has turned profitable in 2024, with improving profitability metrics and a richer variety of mouse strains compared to peers [26][28]. Summary by Sections 1. AHP Score and Expected Allocation Ratio - BaiAoSaiTu's AHP score is 2.38, indicating a mid-to-low level performance in the AHP model [7][8]. 2. Fundamental Highlights and Features 2.1 Gene Editing Technology and Innovative Model Animal Development - BaiAoSaiTu has built platforms for gene editing and model animal breeding, evolving from a single service provider to a leading biopharmaceutical enterprise [8][9]. - The company has developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice [14][15]. 2.2 Antibody and Drug Collaboration Development - The company has created the RenMice platform, known for its high humanization level, facilitating the discovery and development of diverse antibody molecules [16][17]. - BaiAoSaiTu's "Thousand Mice, Ten Thousand Antibodies" initiative aims to discover antibodies against over 1,000 potential drug targets, enhancing its antibody library [17][18]. 2.3 Expansion of Preclinical Pharmacology and Efficacy Evaluation Services - BaiAoSaiTu has established a robust pharmacology and efficacy evaluation system, serving over 950 partners and completing more than 6,350 drug evaluation projects [20][21]. 3. Comparable Company Financial Metrics 3.1 Diverse Product Involvement and Rich Mouse Strain Resources - BaiAoSaiTu's humanized mouse strains exceed 1,700, compared to its peers, providing a competitive edge in preclinical evaluations [25][24]. 3.2 Revenue and Profitability Comparison - The company's revenue from 2022 to 2025 H1 was lower than peers, but it achieved profitability in 2024, with a compound annual growth rate of 35.52% [26][27]. 3.3 Higher Gross Margin and Net Profitability - BaiAoSaiTu's gross margin from 2022 to 2025 H1 averaged above 70%, with a net profit margin improving to 7.73% in 2025 H1, outperforming comparable drug development companies [28][29]. 3.4 R&D Expense Ratio Comparison - The company's R&D expense ratio was above the industry average in 2022 and 2023, reflecting its commitment to extensive research and development [31][32]. 4. Fundraising Projects and Development Vision - The company plans to raise funds for early drug development service platform construction, antibody drug research and evaluation, and preclinical research projects, enhancing its core competitiveness [34][35].

Investment Rating - The report suggests a positive investment outlook for various sectors within the energy industry, particularly hydropower, green energy, nuclear power, and gas companies, indicating potential growth opportunities [6][18][41]. Core Insights - In October 2025, the total electricity consumption in China reached 857.2 billion kWh, marking a year-on-year increase of 10.4%. The growth was primarily driven by the tertiary sector and residential electricity usage, with significant contributions from industries related to big data and AI services [6][9][10]. - Natural gas prices exhibited mixed trends globally, with U.S. prices rising while European prices saw a slight decline. The report highlights the ongoing high demand for LNG in Northeast Asia, which has led to price increases in that region [20][28][41]. - The report emphasizes the importance of various energy sectors, recommending specific companies based on their performance and market conditions, such as hydropower, green energy, nuclear power, and gas companies [18][41]. Summary by Sections 1. Electricity Sector - The electricity consumption in October 2025 was 857.2 billion kWh, with the first, second, and third industries and residential usage showing year-on-year growth rates of 13.2%, 6.2%, 17.1%, and 23.9% respectively [11][12]. - The tertiary sector's electricity consumption grew significantly, particularly in the internet data service industry, which saw a 46% increase [9][10]. - The report notes that the rapid growth in residential electricity usage was influenced by temperature variations, with some regions experiencing over 60% growth [6][9]. 2. Natural Gas Sector - As of November 21, 2025, the Henry Hub spot price in the U.S. was $4.13/mmBtu, reflecting an 18.33% weekly increase, while European gas prices showed slight declines [20][21]. - The report indicates that U.S. natural gas supply and demand remain robust, contributing to the upward price trend, while European prices are stabilizing due to balanced supply and demand [20][28]. - Recommendations for investment include companies in the gas sector that are expected to benefit from cost reductions and increased demand [41]. 3. Investment Recommendations - Hydropower: Continued high growth in hydropower generation is expected, with recommendations for companies like Guotou Power and Chuan Investment Energy [18]. - Green Energy: The report suggests focusing on companies like Xintian Green Energy and Fuhua Co., which are expected to benefit from stable returns and increased operational efficiency [18]. - Nuclear Power: The approval of new nuclear units is anticipated to support growth, with recommendations for China Nuclear Power and China General Nuclear Power [18]. - Gas and Environmental Companies: The report highlights the potential for gas companies to recover profitability and suggests focusing on integrated gas traders [41].

1. Report Industry Investment Rating - Not provided in the report 2. Core Viewpoints of the Report - The number of newly issued US ETF products increased significantly last week, with Calamos issuing a Nasdaq Snowball ETF. The US ETF market shows a decrease in investors' risk preference, and pharmaceutical products have performed well. The US general public - offering funds have seen large - scale outflows from domestic stock funds and small - scale inflows into bond products [1] 3. Summary According to the Directory 3.1 US ETF Innovation Products: Calamos Issues Nasdaq Snowball ETF - Last week, 43 new US ETF products were issued, including 13 individual - stock related products and 7 digital - currency related products. YieldMax's new Performance & Distribution Target 25 series aims for a 25% annual dividend, and GraniteShares' YieldBOOST series issued 2 industry - themed leveraged ETF products [6][8] - Vanguard issued 3 active equity ETFs in cooperation with Wellington, First Trust issued a stock - bond - commodity hybrid ETF, and T. Rowe Price issued 4 bond ETFs. Calamos issued a Nasdaq 100 - linked snowball ETF, which aims for a 35% volatility target and reduces knock - in risk through diversified investment [9] 3.2 US ETF Dynamics 3.2.1 US ETF Funds: Decrease in Risk Preference - In the past week, the inflow of US ETFs exceeded $30 billion. Despite the poor performance of many assets, stock products still had large inflows, while Bitcoin ETFs continued to see outflows. Vanguard's S&P 500 ETF ranked first in inflows, and Nasdaq ETFs and small - cap ETFs had large outflows, indicating a decrease in risk preference [10][13] 3.2.2 US ETF Performance: Pharmaceutical Products Perform Well - Recently, the pharmaceutical sector has been the second - highest - rising sector in the US (after raw materials). Biotech products have increased by over 20% this year, and broad - based pharmaceutical products generally have returns of over 10% [16] 3.3 Recent Capital Flows of US General Public - Offering Funds - In September 2025, the total amount of non - money public - offering funds in the US was $23.47 trillion, an increase of $0.49 trillion from August. The S&P 500 rose 3.53% in September, and the scale of domestic stock products increased by 2.13%, but the redemption pressure increased. Last week, domestic stock funds continued to see outflows of around $20 billion, with nearly $600 billion in outflows this year, while bond products had small - scale inflows [1][20]

Investment Rating - The report maintains a positive outlook on the power and gas sectors, recommending various companies within these industries based on their performance and market conditions [2]. Core Insights - The report highlights a significant increase in electricity consumption in October, with a year-on-year growth of 10.4%, driven primarily by the tertiary sector and residential usage [5][10]. - Natural gas prices exhibit mixed trends globally, with U.S. prices rising while European prices are stabilizing [22][30]. - The report provides specific investment recommendations across various segments, including hydropower, green energy, nuclear power, thermal power, and gas [20][21]. Summary by Sections 1. Electricity Sector - In October, total electricity consumption reached 857.2 billion kWh, marking a 10.4% increase year-on-year. The first, second, and third industries, along with residential consumption, saw growth rates of 13.2%, 6.2%, 17.1%, and 23.9%, respectively [12][10]. - The tertiary sector's electricity consumption grew the fastest, particularly in internet data services related to big data and AI, which surged by 46% [11]. - The report notes that the second industry contributes over 60% of total electricity consumption, with high-tech and equipment manufacturing showing significant growth [11][12]. 2. Gas Sector - As of November 21, U.S. Henry Hub spot prices were $4.13/mmBtu, reflecting an 18.33% weekly increase, while European gas prices showed slight declines [22][30]. - The report indicates that U.S. natural gas supply remains robust, with a notable increase in LNG demand, contributing to rising prices [24][25]. - Recommendations include focusing on integrated gas companies and those benefiting from cost reductions and increased sales, such as Kunlun Energy and New Hope Energy [44]. 3. Weekly Market Review - The report notes that the public utility, gas, and power equipment sectors underperformed compared to the Shanghai and Shenzhen 300 index during the week of November 17 to November 21 [47]. 4. Company and Industry Dynamics - The report discusses the commissioning of China's highest-altitude wind power project in Tibet, which is expected to provide significant clean energy and economic benefits to the local community [50][53]. - It also highlights various local government initiatives aimed at promoting green electricity and renewable energy projects, including direct connections for green electricity [54][55].

Group 1 - The market sentiment score decreased slightly to 3.8 as of November 21, down from 3.9 the previous week, indicating a bearish outlook from a sentiment perspective [6][10][11] - The overall trading activity in the market has declined, with total trading volume for the week down 8.74% compared to the previous week, averaging 18650.36 billion CNY per day [13][15] - The short-term trend scores for industries such as banking, textiles, defense, and petrochemicals have shown an upward trend, with petrochemicals having the highest short-term score of 83.05 [35][36] Group 2 - The price-volume consistency indicator has rapidly declined, suggesting a decrease in the correlation between capital attention and stock price increases, leading to a drop in market sentiment [10][11][12] - The industry trading volatility has continued to rise, indicating increased activity in capital switching between sectors, although the growth rate has slowed down [19][21] - The financing balance ratio has continued to rise, reflecting an increase in leveraged capital sentiment, suggesting a more active investment environment [25][27] Group 3 - The model indicates a preference for small-cap and value styles, with strong signals for both, although the 5-day RSI relative to the 20-day RSI has decreased rapidly, warranting further observation [35][44] - The industry crowding degree shows a negative correlation with weekly price changes, indicating that sectors with high crowding, such as electric power equipment and basic chemicals, have experienced significant declines [39][41] - The report highlights that industries with lower crowding, such as automobiles and machinery, have shown smaller declines, suggesting potential long-term investment value [39][41]

E Vice I 2025 年 11 月 24 日 看好 相关研究 证券分析师 韩强 A0230518060003 hanqiang@swsresearch.com 武雨桐 A0230520090001 wuyt@swsresearch.com 穆少阳 A0230524070009 musy@swsresearch.com 册 分歧污 达邵炜 A0230124030001 dasw@swsresearch.com 联系人 达邵炜 A0230124030001 dasw@swsresearch.com 期待"十五五"订单陆续落 大军工行业关注度 国防军工行业周报（2025年第 48 周） 本期投资提示: 上周申万国防军工指数下跌 1.72%，中证军工龙头指数下跌 2.87%，同期上证综指下 跌 3.9%, 沪深 300 下跌 3.77%, 创业板指下跌 6.15%, 申万国防军工指数跑赢创业 板指、跑赢沪深 300、跑赢上证综指、跑赢军工龙头指数。1、从细分板块来看，上周 国防军工板块 1.72%的跌幅在 31 个申万一级行业涨跌幅排名第 4 位。2、从我们构建的 军工集团指数变化来看，上周中证民参军涨跌幅排名 ...

行 业 及 产 业 国防军工 相关研究 证券分析师 韩强 A0230518060003 hanqiang@swsresearch.com 武雨桐 A0230520090001 wuyt@swsresearch.com 穆少阳 A0230524070009 musy@swsresearch.com 研究支持 达邵炜 A0230124030001 dasw@swsresearch.com 联系人 达邵炜 A0230124030001 dasw@swsresearch.com 2025 年 11 月 24 日 期待"十五五"订单陆续落地，加 大军工行业关注度 看好 ——国防军工行业周报（2025 年第 48 周） 本期投资提示： ⚫ 上周申万国防军工指数下跌 1.72%，中证军工龙头指数下跌 2.87%，同期上证综指下 跌 3.9%，沪深 300 下跌 3.77%，创业板指下跌 6.15%，申万国防军工指数跑赢创业 板指、跑赢沪深 300、跑赢上证综指、跑赢军工龙头指数。1、从细分板块来看，上周 国防军工板块 1.72%的跌幅在 31 个申万一级行业涨跌幅排名第 4 位。2、从我们构建的 军工集团指数变化来看，上周 ...

Group 1 - Market sentiment score has slightly decreased to 3.8 as of November 21, down from 3.9 the previous week, indicating a bearish outlook [7][11] - The consistency between price and volume has weakened significantly, showing a decline in market engagement and a drop in risk appetite, particularly reflected in the decreasing trading volume of the Sci-Tech 50 index [11][18] - The total trading volume for the entire A-share market has decreased by 8.74% week-on-week, with an average daily trading volume of 18650.36 billion yuan [15][17] Group 2 - The banking, textile and apparel, defense, petrochemical, and comprehensive sectors have shown an upward trend in short-term scores, with the petrochemical sector leading at a score of 83.05 [40][41] - The correlation between sector crowding and weekly price changes is negative at -0.24, indicating that sectors with high crowding, such as electric power equipment and basic chemicals, have experienced significant declines [44][46] - The current model indicates a preference for small-cap and value styles, with strong signals for both, although the strength of these signals may need further observation [50][52]